Alerts will be sent to your verified email
Verify EmailRUBICON
Rubicon Research
|
Sun Pharma Inds.
|
Aurobindo Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
72.0 . | 661.0 . | 865.0 . |
Number of ANDA's Approved
|
5.0 . | n/a | n/a |
Unclassified
|
|||
R&D as a % of Total Sales
|
10.42 % | 6.5 % | 4.7 % |
Financials
|
|||
5 yr Average ROE
|
5.76 % | 11.67 % | 12.72 % |
5yr average Equity Multiplier
|
2.29 | 1.33 | 1.46 |
5yr Average Asset Turnover Ratio
|
0.66 | 0.57 | 0.68 |
5yr Avg Net Profit Margin
|
1.04 % | 15.4 % | 12.5 % |
Price to Book
|
n/a | 5.5 | 1.97 |
P/E
|
n/a | 38.26 | 19.0 |
5yr Avg Cash Conversion Cycle
|
-23.11 Days | -46.88 Days | -46.37 Days |
Inventory Days
|
96.45 Days | 65.22 Days | 59.62 Days |
Days Receivable
|
88.85 Days | 84.33 Days | 30.33 Days |
Days Payable
|
228.02 Days | 175.41 Days | 121.28 Days |
5yr Average Interest Coverage Ratio
|
2.59 | 44.12 | 43.54 |
5yr Avg ROCE
|
12.78 % | 18.0 % | 15.27 % |
5yr Avg Operating Profit Margin
|
13.16 % | 26.44 % | 19.22 % |
5 yr average Debt to Equity
|
0.74 | 0.06 | 0.19 |
5yr CAGR Net Profit
|
34.36 % | 30.35 % | -8.16 % |
5yr Average Return on Assets
|
1.79 % | 8.92 % | 8.64 % |
Shareholdings
|
|||
Promoter Holding
|
n/a | 54.48 % | 51.82 % |
Share Pledged by Promoters
|
n/a | 0.88 % | 17.5 % |
Change in Promoter Holding (3 Yrs)
|
n/a | 0.0 | -0.01 % |
Change in Mutual Fund Holding (3 Yrs)
|
n/a | 0.79 % | 10.34 % |
Rubicon Research
|
Sun Pharma Inds.
|
Aurobindo Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|
Asset Break-Up - Geography Wise
|
Asset Break-Up - Geography Wise
|
-
|
-
|